Skip to main content
SpringerLink
Log in

Aztreonam lysine for inhalation solution: a guide to its use in cystic fibrosis

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

References

  1. Plosker GL. Aztreonam lysine for inhalation solution in cystic fibrosis. Drugs 2010; 70(14): 1843–55

    Article  PubMed  CAS  Google Scholar 

  2. Cayston powder and solvent for nebuliser solution: summary of product characteristics. London: European Medicines Agency, 2010 Sep

  3. Cayston® (aztreonam for inhalation solution): US prescribing information. Foster City (CA): Gilead Sciences, Inc., 2010 Feb

  4. McCoy K, Retsch-Bogart G, Gibson RL, et al. Microbiologic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF) [poster no. 142]. 31st European Cystic Fibrosis Conference; 2008 Jun 11–14; Prague

  5. McCoy K, Retsch-Bogart G, Gibson RL, et al. Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis [poster no. 418]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23–25; Orlando (FL)

  6. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010 Nov; 45(11): 1121–34

    Article  PubMed  Google Scholar 

  7. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135(5): 1223–32

    Article  PubMed  CAS  Google Scholar 

  8. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178(9): 921–8

    Article  PubMed  CAS  Google Scholar 

  9. Wainwright C, Nakamura C, Geller DE, et al. A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa (PA) [abstract no. 81]. 33rd European Cystic Fibrosis Society Conference; 2010 Jun 16–19; Valencia

  10. Assael BM, La Rosa M, Knoop C, et al. Aztreonam for inhalation solution (AZLI) head to head trial, a comparative trial vs. tobramycin nebuliser solution (TNS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (PA): results of first treatment cycle [abstract]. 33rd European Cystic Fibrosis Society Conference; 2010 Jun 16–19; Valencia

  11. Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnarie-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009; 135(6): 1610–8

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aztreonam lysine for inhalation solution: a guide to its use in cystic fibrosis. Drugs Ther. Perspect 27, 1–4 (2011). https://doi.org/10.1007/BF03257127

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03257127

Search

Navigation